Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEPRE trial of letrozole versus standard chemotherapy in hormone receptor-positive low-grade serous ovarian cancer
2020-003066-39Phase 3Active
- Sponsor
- Ospedali Galliera
- Start
- Jan 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribociclib + letrozole, carboplatin and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Ospedali Galliera. Primary endpoint: Progression-free survival. Started Jan 2022; status: active.
02
Drugs
ribociclib + letrozolecarboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-003066-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003066-39.